Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis

Katja Weisel; Meletios A Dimopoulos; Niels W.C.J. van de Donk; Karthik Ramasamy; Barbara Gamberi; Matthew Streetly; Massimo Offidani; Frank Bridoux; Javier de la Rubia; Elisabeth Kueenburg; Shona Collins; Frederik Lersch; Barbara Rosettani; Pamela Bacon; Pieter Sonneveld

doi:10.1016/j.clml.2017.03.261

Article2015

An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Meletios A Dimopoulos, Antonio Palumbo, Paolo Corradini, Michèle Cavo, Michel Delforge, Katja Weisel, Enrique M. Ocio, Francesco Di Raimondo, Markus Hansson, Mathew Simcock, Neil Miller, Ana Slaughter, Teresa Peluso, Lars Sternås, Mohamed H. Zaki, Philippe Moreau

Article2015

Treatment (Tx) With Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Including Those on Dialysis

Pieter Sonneveld, Meletios A Dimopoulos, Karthik Ramasamy, Elisabeth Kueenburg, Barbara Rosettani, Shona Collins, P. Bacon, Katja Weisel

Article2016

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Katja Weisel, Meletios A Dimopoulos, Niels W.C.J. van de Donk, Karthik Ramasamy, Barbara Gamberi, Matthew Streetly, Massimo Offidani, Frank Bridoux, Javier de la Rubia, Elisabeth Kueenburg, Frederik Lersch, Barbara Rosettani, Pamela Bacon, Pieter Sonneveld

Article2013

Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.

Kevin Song, Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol Rocafiguera, Stacie Hudgens, Zhinuan Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel

Article2013

Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.

Hartmut Goldschmidt, Meletios A Dimopoulos, Katja Weisel, Philippe Moreau, Martha Q. Lacy, Kevin Song, Michel Delforge, Lionel Karlin, Anne Banos, Albert Oriol Rocafiguera, Xin Yu, Lars Sternås, Christian Jacques, Mohamed H. Zaki, Jesús F. San Miguel

Phase 2 Multicenter Study of Pomalidomide (POM) Plus Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI): An Updated Safety Analysis

Discussion(0)

Related publications

An Updated Analysis of the Stratus Trial (MM-010): Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Treatment (Tx) With Pomalidomide (POM) and Low-Dose Dexamethasone (LoDEX) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Including Those on Dialysis

Safety Results of a Phase 2 Multicenter, Open-Label Study of Pomalidomide (CC-4047) Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment

Quality of life (QOL) improvements for pomalidomide plus low-dose dexamethasone (POM + LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients (pts) enrolled in MM-003.

Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.